Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center open-label proof-of-concept study consisting of two parts: PART A - a
phase I dose-finding study (3 + 3 classical design) evaluating the RP2D of afatinib in
combination with selumetinib in KRASm NSCLC; and PART B - a randomized phase II study
investigating the progression free survival and safety of selumetinib/afatinib combination
therapy compared to standard of care chemotherapy in KRASm NSCLC.